Provided by Tiger Trade Technology Pte. Ltd.

PagerDuty, Inc.

6.01
-0.3000-4.75%
Post-market: 6.030.0200+0.33%19:55 EDT
Volume:2.51M
Turnover:15.15M
Market Cap:510.73M
PE:3.21
High:6.25
Open:6.21
Low:5.92
Close:6.31
52wk High:18.97
52wk Low:5.92
Shares:84.98M
Float Shares:80.63M
Volume Ratio:0.85
T/O Rate:3.12%
Dividend:- -
Dividend Rate:- -
EPS(TTM):1.87
EPS(LYR):1.87
ROE:82.50%
ROA:0.48%
PB:2.01
PE(LYR):3.21

Loading ...

Konruns Pharma's KC1036 Combined with Immunotherapy Gets Green Light for Advanced Cancer Trials

Stock News
·
Mar 04

Press Release: Apogee Therapeutics Provides Pipeline Progress and Reports Full Year 2025 Financial Results

Dow Jones
·
Mar 02

Cathie Wood Leverages Baidu’s Post-Earnings Dip, Sells PagerDuty

TIPRANKS
·
Feb 28

Aclaris Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

GlobeNewswire
·
Feb 26

Alector Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

GlobeNewswire
·
Feb 26

Antengene Announces Clinical Collaboration with Junshi Biosciences to Explore the Synergistic Potential of ATG-037 (Oral CD73 Inhibitor) In Combination with JS207 (PD-1/VEGF BsAb)

prnewswire
·
Feb 25

Rail Vision: Quantum Transportation Advancing Toward Quantum Hardware Integration

GlobeNewswire
·
Feb 24

Supernus Pharmaceuticals to Participate in March Investor Conferences

GlobeNewswire
·
Feb 24

CSTONE PHARMA-B Receives FDA Clearance for Phase II Trial of CS2009

Stock News
·
Feb 20

Press Release: PagerDuty to Report Fourth Quarter and Full Fiscal Year 2026 Results on March 12, 2026

Dow Jones
·
Feb 20

PagerDuty Inc. Published an Update to Its Financial Calendar

Reuters
·
Feb 20

Morgan Stanley Lowers PagerDuty Price Target to $9 From $16

MT Newswires Live
·
Feb 20

PagerDuty price target lowered to $9 from $16 at Morgan Stanley

TIPRANKS
·
Feb 19

CStone Pharmaceuticals' CS2009 Tri-Specific Antibody Phase II Trial Receives FDA Clearance

Stock News
·
Feb 16

Sino Biopharm Wins China Nod for New Lung Cancer Use of PD-L1 Drug

TIPRANKS
·
Feb 16

Annovis Secures DSMB Approval to Advance Pivotal Phase 3 Trial of Buntanetap in Alzheimer’s Disease

GlobeNewswire
·
Feb 12

Agilent gets FDA approval for PD-L1 IHC 22C3 pharmDx

TIPRANKS
·
Feb 12

RBC Cuts Price Target on PagerDuty to $9 From $15, Keeps Sector Perform Rating

MT Newswires Live
·
Feb 11

PagerDuty Inc. Files Initial Statement of Beneficial Ownership for Director Scott Aronson

Reuters
·
Feb 11

MerryLife Biomedical Reports Positive Phase 1 Results and Plans for Global Phase 2 Trial for TML-6, an Oral Multi-Targeted Investigational Therapy for Alzheimer's Disease

prnewswire
·
Feb 10